A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4156 participants.
Also called NCT01455896
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,156 participants
- Sponsor
- Registry
-
NCT01455896
-
- Other papers using this trial's data
- Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Denmark, Finland, Germany, Poland, Slovakia, South Africa, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01455896. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (actual); primary completion 2016-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ITCA 650
- Intervention (Other)
- ITCA placebo
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct01455896- Content hash
afb37c498478549f39dc95c90a4767fff818464ad967d4b84348c99b0e1140d4